Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1996-12-04
2000-04-18
Scheiner, Toni R.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241431, 4241391, 4241351, 4241331, 4241301, 424 851, 424 852, 4241841, 424 937, A61K 39395, A61K 3819
Patent
active
06051227&
ABSTRACT:
T cell activation in response to antigen is increased by the administration of binding agents that block CTLA-4 signaling. When CTLA-4 signaling is thus blocked, the T cell response to antigen is released from inhibition. Such an enhanced response is useful for the treatment of tumors, chronic viral infections, and as an adjuvant during immunization.
REFERENCES:
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5556763 (1996-09-01), Ochoa et al.
patent: 5811097 (1998-09-01), Allison et al.
Wu et al., "CTLA-4-B7 Interaction is Sufficient to Costimulate T Cell Clonal Expansion," J. Exp. Med. 185(7):1327-1335 (1997).
Linsley, P.S., "Distinct Roles for CD28 and Cytotoxic Lymphocyte-Associated Molecule-4-Receptors During T Cell Activation," J. Exp. Med., 182:289-292 (1995).
June et al., "The B7 and CD28 Receptor Families," Immunology Today, 15(7):321-331 (1994).
Linsley et al., "Coexpression and Functional Cooperation of CTLA-4 anc CD28 on Activated T Lymphocytes," J. Exp. Med. 176:1595-1604 (1992).
Chen et al., "Costimulation of Antitumor Immunity by the B7 Counterreceptor for the T Lymphocyte Molecules CD28 and CTLA-4," Cell 71:1093-1102 (1992).
Freeman et al., "Uncovering of Functional Alternative CTLA-4 Counter-Receptor in B7-Deficient Mice," Science 262:907-909 (1993).
Lenschow et al., "Expression and Functional Significance of an Additional Ligand for CTLA-4," Proc. Natl. Acad. Sci. USA 90:11054-11058 (1993).
Jenkins, M.K., "The Ups and Downs of T Cell Costimulation," Immunity 1:443-446 (1994).
Walunas et al., "CTLA-4 Can Function as a Negative Regulator of T Cell Activation," Immunity 1:405-413 (1994).
Schwartz, R.H., "Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy," Cell 71:1065-1068 (1992).
Linsley et al., "CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7," J. Exp. Med. 174:561-569 (1991).
Linsley et al., "Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule," Science 257:792-795 (1992).
Lenschow et al., "Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg," Science 257:789-792 (1992).
Brunet et al., "A New Member of the Immunoglobulin Superfamily-CTLA-4," Nature 328:267-270 (1987).
Harding et al., "CD28-Mediated Signalling Co-Stimulates Murine T Cells and Prevents Induction of Anergy in T-Cell Clones," Nature 356:607-609 (1992).
Townsend, S.E. and J.P. Allison, "Tumor Rejection After Direct Costimulation of CD8+ T Cells by B7-Transfected Melanoma Cells," Science 259:368-370 (1993).
Damle et al., "Costimulation of T Lymphocytes with Integrin Ligands Intercellular Adhesion Molecule-1 or Vascular Cell Adhesion Molecule-1 Induces Functional Expression of CTLA-4, A Second Receptor for B7," Journal of Immunology 152:2686-2697 (1994).
Lin et al., "Long-Term Acceptance of Major Histocompatibility Complex Mismatched Cardiac Allografts Induced by CTLA4lg Plus Donor-Specific Transfusion," J. Exp. Med. 178:1801-1806 (1993).
Turka et al., "T-Cell Activation by the CD28 Ligand B7 is Required for Cardiac Allograft Rejection in vivo," Proc. Natl. Acad. Sci. USA 89:11102-11105 (1992).
Linsley, P.S. and J.A. Ledbetter, "The Role of the CD28 Receptor During T Cell Responses to Antigen," Ann. Rev. Immunol. 11:191-212 (1993).
Gribben et al. Proc. Natl. Acad. Sci. USA 92:811-815 (1995).
Bluestone Immunity 2:555-559 (1995).
Kearney et al., "Antigen-Deptendent Clonal Expansion of a Trace Population of Antigen-Specific CD4.sup.+ T Cells in Vivo Is Dependent on CD28 Contimulation and Inhibited by CTLA-4.sup.1," The Journal of Immunology 155:1032-1036 (1995).
Allison James Patrick
Krummel Matthew F.
Leach Dana R.
Lorenz Todd A.
Scheiner Toni R.
The Regents of the University of California, Office of Technolog
Trecartin Richard F.
LandOfFree
Blockade of T lymphocyte down-regulation associated with CTLA-4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Blockade of T lymphocyte down-regulation associated with CTLA-4 , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blockade of T lymphocyte down-regulation associated with CTLA-4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2334412